SERA Nasdaq Services-Medical Laboratories Financials FY2020βFY2025
Sera Prognostics, Inc. had $0.1M of revenue in fiscal 2025, up 5.2% on the year before. Over five years, revenue changed +26.5% a year on average.
Last close Β· Oct 23, 2026
$2.03
0.5%Hi! I read Sera Prognostics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+5.2%
Yes. Sales grew 5.2% last year.
Does it make a profit?
β39,417.3%
No. It lost money last year.
Does profit turn into cash?
β32,529.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Sera Prognostics, Inc. had $0.1M of revenue in fiscal 2025, up 5.2% on the year before. Over five years, revenue changed +26.5% a year on average. Its operating margin was β45,066.7%, up 2,511.3Β pts: of every 100 in sales, about β45,067 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Sera Prognostics, Inc. lost $31.9M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$26.3M in fiscal 2025, β32,529.6% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $0.7M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.7M
10 insiders
Of sales under plans
7%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 12, 2026 | Tiffany Eul Davis InglisChief Medical Officer | Sold | 8,024 | $2.03 | $0.0M | Form 4 |
| Sep 10, 2026 | Zhenya LindgardtChief Executive Officer, Director | Sold | 7,022 | $2.00 | $0.0M | Form 4 |
| Sep 10, 2026 | Tiffany Eul Davis InglisChief Medical Officer | Sold | 486 | $2.00 | $0.0M | Form 4 |
| Sep 10, 2026 | Dyaarl Lee Anderson Jr.Chief Commercial Officer | Sold | 1,800 | $2.00 | $0.0M | Form 4 |
| Sep 10, 2026 | Benjamin JacksonGeneral Counsel | Sold | 2,190 | $2.00 | $0.0M | Form 4 |
| Sep 8, 2026 | Zhenya LindgardtChief Executive Officer, Director | Sold | 20,139 | $2.00 | $0.0M | Form 4 |
| Jun 11, 2026 | Benjamin JacksonGeneral Counsel | Sold | 2,179 | $2.01 | $0.0M | Form 4 |
| Jun 11, 2026 | Tiffany Eul Davis InglisChief Medical Officer | Sold | 362 | $2.01 | $0.0M | Form 4 |
| Jun 11, 2026 | Dyaarl Lee Anderson Jr.Chief Commercial Officer | Sold | 4,739 | $2.01 | $0.0M | Form 4 |
| Jun 11, 2026 | Austin AertsChief Financial Officer | Sold | 2,037 | $2.01 | $0.0M | Form 4 |
| Jun 11, 2026 | Zhenya LindgardtChief Executive Officer, Director | Sold | 6,990 | $2.01 | $0.0M | Form 4 |
| Jun 9, 2026 | Zhenya LindgardtChief Executive Officer, Director | Sold | 20,755 | $2.08 | $0.0M | Form 4 |
| Jun 9, 2026 | Austin AertsChief Financial Officer | Sold | 5,440 | $2.08 | $0.0M | Form 4 |
| Jun 8, 2026 | Sandra AJ LawrenceDirector | Sold plan | 1,560 | $2.15 | $0.0M | Form 4 |
| Mar 11, 2026 | Zhenya LindgardtChief Executive Officer, Director | Sold | 2,973 | $2.04 | $0.0M | Form 4 |
| Mar 11, 2026 | Benjamin JacksonGeneral Counsel | Sold | 1,027 | $2.04 | $0.0M | Form 4 |
| Mar 11, 2026 | Austin AertsChief Financial Officer | Sold | 1,019 | $2.04 | $0.0M | Form 4 |
| Mar 11, 2026 | John J. BonifaceChief Scientific Officer | Sold | 1,517 | $2.04 | $0.0M | Form 4 |
| Mar 11, 2026 | Robert Gardner HarrisonChief Information Officer | Sold | 716 | $2.04 | $0.0M | Form 4 |
| Mar 11, 2026 | Paul KearneyChief Data Officer | Sold | 1,396 | $2.04 | $0.0M | Form 4 |
| Mar 10, 2026 | Zhenya LindgardtChief Executive Officer, Director | Sold | 22,639 | $1.90 | $0.0M | Form 4 |
| Mar 10, 2026 | Austin AertsChief Financial Officer | Sold | 6,069 | $1.90 | $0.0M | Form 4 |
| Mar 9, 2026 | Paul KearneyChief Data Officer | Sold | 2,026 | $1.96 | $0.0M | Form 4 |
| Mar 9, 2026 | Robert Gardner HarrisonChief Information Officer | Sold | 3,360 | $1.96 | $0.0M | Form 4 |
| Mar 9, 2026 | Austin AertsChief Financial Officer | Sold | 674 | $1.96 | $0.0M | Form 4 |
| Mar 9, 2026 | Benjamin JacksonGeneral Counsel | Sold | 3,119 | $1.96 | $0.0M | Form 4 |
| Mar 9, 2026 | John J. BonifaceChief Scientific Officer | Sold | 3,038 | $1.96 | $0.0M | Form 4 |
| Mar 6, 2026 | Sandra AJ LawrenceDirector | Sold plan | 1,560 | $1.95 | $0.0M | Form 4 |
| Feb 24, 2026 | Robert Gardner HarrisonChief Information Officer | Sold plan | 2,000 | $2.34 | $0.0M | Form 4 |
| Jan 27, 2026 | Robert Gardner HarrisonChief Information Officer | Sold plan | 2,000 | $2.97 | $0.0M | Form 4 |
| Dec 30, 2025 | Robert Gardner HarrisonChief Information Officer | Sold plan | 2,000 | $3.00 | $0.0M | Form 4 |
| Dec 10, 2025 | Paul KearneyChief Data Officer | Sold | 1,213 | $3.31 | $0.0M | Form 4 |
| Dec 10, 2025 | Austin AertsChief Financial Officer | Sold | 873 | $3.31 | $0.0M | Form 4 |
| Dec 10, 2025 | Benjamin JacksonGeneral Counsel | Sold | 892 | $3.31 | $0.0M | Form 4 |
| Dec 10, 2025 | Zhenya LindgardtChief Executive Officer, Director | Sold | 4,155 | $3.31 | $0.0M | Form 4 |
| Dec 10, 2025 | Robert Gardner HarrisonChief Information Officer | Sold | 616 | $3.31 | $0.0M | Form 4 |
| Dec 10, 2025 | John J. BonifaceChief Scientific Officer | Sold | 1,332 | $3.31 | $0.0M | Form 4 |
| Dec 9, 2025 | Austin AertsChief Financial Officer | Sold | 5,232 | $3.04 | $0.0M | Form 4 |
| Dec 9, 2025 | Zhenya LindgardtChief Executive Officer, Director | Sold | 28,215 | $3.04 | $0.1M | Form 4 |
| Dec 8, 2025 | Sandra AJ LawrenceDirector | Sold plan | 1,560 | $3.05 | $0.0M | Form 4 |
| Dec 5, 2025 | Mansoor Raza MirzaDirector | Sold | 292 | $3.05 | $0.0M | Form 4 |
| Dec 2, 2025 | Robert Gardner HarrisonChief Information Officer | Sold plan | 2,000 | $2.93 | $0.0M | Form 4 |
| Dec 2, 2025 | Paul KearneyChief Data Officer | Sold | 32,203 | $2.94 | $0.1M | Form 4 |
| Nov 26, 2025 | Paul KearneyChief Data Officer | Sold plan | 1,986 | $3.51 | $0.0M | Form 4 |
| Nov 10, 2025 | John J. BonifaceChief Scientific Officer | Sold | 7,767 | $2.62 | $0.0M | Form 4 |
| Nov 10, 2025 | Zhenya LindgardtChief Executive Officer, Director | Sold | 11,594 | $2.62 | $0.0M | Form 4 |
| Nov 10, 2025 | Robert Gardner HarrisonChief Information Officer | Sold | 6,528 | $2.62 | $0.0M | Form 4 |
| Nov 10, 2025 | Benjamin JacksonGeneral Counsel | Sold | 7,059 | $2.62 | $0.0M | Form 4 |
| Nov 10, 2025 | Paul KearneyChief Data Officer | Sold | 7,073 | $2.62 | $0.0M | Form 4 |
| Nov 10, 2025 | Austin AertsChief Financial Officer | Sold | 6,351 | $2.62 | $0.0M | Form 4 |
| Nov 5, 2025 | Mansoor Raza MirzaDirector | Sold | 221 | $3.04 | $0.0M | Form 4 |
| Nov 4, 2025 | Robert Gardner HarrisonChief Information Officer | Sold plan | 2,000 | $3.07 | $0.0M | Form 4 |
| Oct 7, 2025 | Robert Gardner HarrisonChief Information Officer | Sold plan | 2,000 | $3.18 | $0.0M | Form 4 |
| Oct 6, 2025 | Mansoor Raza MirzaDirector | Sold | 227 | $3.16 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Sera Prognostics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $105M | $82.7M | $49.1M | $46.2M | $39.2M |
| Interest coverage | β | β | β724.0x | β1,308.4x | β4,056.0x |
| Current ratio | 13.1x | 5.8x | 2.5x | 1.9x | 1.7x |
| Quick ratio | 13.1x | 5.8x | 2.5x | 1.9x | 1.7x |
| Total assets | $147M | $116M | $95.4M | $72.6M | $102M |
| Total liabilities | $8.5M | $17.4M | $25.3M | $24.8M | $26.5M |
| Shareholders' equity | $139M | $98.9M | $70.2M | $47.8M | $75.4M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Sera Prognostics, Inc. passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 2 / 7 | 3 / 7 | 1 / 8 | 2 / 8 |
| Accruals ratio | β20.1% | β4.2% | β7.3% | β8.6% | β22.3% | β7.2% |
| Altman Z'' | β46.72 | 16.42 | 1.64 | β5.79 | β11.87 | β8.32 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $0.0M | $0.1M | $0.3M | $0.3M | $0.1M | $0.1M |
| Gross profit | β | β | β | $0.1M | β$0.0M | β$0.1M |
| Research and development | $7.8M | $11.0M | $14.2M | $15.2M | $14.7M | $13.2M |
| Operating income | β$18.0M | β$35.4M | β$45.7M | β$39.8M | β$36.6M | β$36.5M |
| Interest expense | β | β | β | $0.1M | $0.0M | $0.0M |
| Pretax income | β | β | β | β | β$32.9M | β$31.9M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$19.8M | β$35.0M | β$44.2M | β$36.2M | β$32.9M | β$31.9M |
| Diluted EPS | β$12.76 | β$2.33 | β$1.43 | β$1.16 | β$0.99 | β$0.67 |
| Diluted shares | 0.00B | 0.02B | 0.03B | 0.03B | 0.03B | 0.05B |
| Cash flow | ||||||
| Cash from operations | β$16.9M | β$31.6M | β$34.6M | β$27.2M | β$14.2M | β$25.6M |
| Capital expenditure | $0.1M | $1.3M | $0.8M | $0.1M | $0.1M | $0.7M |
| Free cash flow | β$17.0M | β$32.9M | β$35.4M | β$27.3M | β$14.2M | β$26.3M |
| Depreciation and amortization | $0.9M | $0.7M | $0.8M | $0.9M | $0.8M | $0.9M |
| Stock-based compensation | $0.7M | $3.1M | $5.1M | $5.3M | $7.0M | $5.1M |
| Balance sheet | ||||||
| Cash and short-term investments | $13.5M | $105M | $82.7M | $49.1M | $46.2M | $39.2M |
| Finance lease liabilities | β | β | $1.1M | $0.6M | $0.2M | $0.0M |
| Current assets | $13.7M | $110M | $90.1M | $61.3M | $47.6M | $40.8M |
| Current liabilities | $11.2M | $8.4M | $15.5M | $24.4M | $24.8M | $24.2M |
| Property and equipment, net | $1.0M | $1.8M | β | β | β | β |
| Intangible assets | β | β | β | $0.0M | $1.0M | $0.9M |
| Total assets | $14.8M | $147M | $116M | $95.4M | $72.6M | $102M |
| Total liabilities | $12.3M | $8.5M | $17.4M | $25.3M | $24.8M | $26.5M |
| Shareholders' equity | β$126M | $139M | $98.9M | $70.2M | $47.8M | $75.4M |
| Margins | ||||||
| Gross margin | β | β | β | 31.4% | β6.5% | β102.5% |
| Operating margin | β71,884.0% | β43,164.6% | β17,034.3% | β13,013.4% | β47,577.9% | β45,066.7% |
| EBITDA margin | β68,304.0% | β42,361.0% | β16,752.2% | β12,719.3% | β46,496.1% | β43,906.2% |
| Net margin | β79,392.0% | β42,693.9% | β16,487.3% | β11,843.8% | β42,724.7% | β39,417.3% |
| FCF margin | β68,068.0% | β40,170.7% | β13,209.3% | β8,926.8% | β18,500.0% | β32,529.6% |
| Returns | ||||||
| Return on capital employed | β505.7% | β25.5% | β45.3% | β56.1% | β76.6% | β47.0% |
| Return on equity | β | β538.8% | β37.2% | β42.9% | β55.8% | β51.8% |
| Return on assets | β134.1% | β43.3% | β33.6% | β34.2% | β39.2% | β36.6% |
| Return on tangible equity | β | β25.3% | β44.7% | β51.7% | β70.3% | β42.9% |
| Growth | ||||||
| Revenue growth | β | 228.0% | 226.8% | 14.2% | β74.8% | 5.2% |
| Share count change | β | 864.4% | 106.2% | 0.8% | 6.3% | 43.7% |
| Financial health | ||||||
| Interest coverage | β | β | β | β724.0x | β1,308.4x | β4,056.0x |
| Current ratio | 1.2x | 13.1x | 5.8x | 2.5x | 1.9x | 1.7x |
| Quick ratio | 1.2x | 13.1x | 5.8x | 2.5x | 1.9x | 1.7x |
| Capital allocation | ||||||
| Capex / revenue | 596.0% | 1,590.2% | 295.1% | 41.8% | 72.7% | 896.3% |
| Stock comp / revenue | 2,904.0% | 3,817.1% | 1,886.2% | 1,723.2% | 9,107.8% | 6,308.6% |
| Quality scores | ||||||
| Piotroski F-score | β | 3.0 | 2.0 | 3.0 | 1.0 | 2.0 |
| Altman Z'' | β46.7 | 16.4 | 1.6 | β5.8 | β11.9 | β8.3 |
| Accruals ratio | β20.1% | β4.2% | β7.3% | β8.6% | β22.3% | β7.2% |
Source: SEC EDGAR XBRL filings (CIK 0001534969). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
